Amylyx Pharmaceuticals, Inc. (AMLX) vs Prestige Consumer Healthcare Inc. (PBH)
- Amylyx Pharmaceuticals, Inc. AMLX 26.34 −4.74%
- Prestige Consumer Healthcare Inc. PBH 49.92 +1.46%
Amylyx Pharmaceuticals, Inc. and Prestige Consumer Healthcare Inc. are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.3B — 1.5× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.9×. Prestige Consumer Healthcare Inc. grew revenue faster over the last twelve months: −1.36% against −77.1%. Prestige Consumer Healthcare Inc. has the higher net margin (15.6% vs 0.00%) and the higher return on invested capital (4.70% vs 0.00%). Across the 18 metrics below, Prestige Consumer Healthcare Inc. leads on 14 and Amylyx Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | AMLX | PBH | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 53.53% | 53.94% |
| Operating margin | 0.00% | 26.26% | 0.00% |
| Net margin | 0.00% | 15.57% | 0.00% |
| Free cash flow margin | 0.00% | 21.30% | 0.00% |
| Return on equity | (74.73%) | 9.12% | (0.40%) |
| Return on assets | (66.25%) | 4.30% | (3.32%) |
| Return on invested capital | 0.00% | 4.70% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack